Dow Jones 10407.68 -24.84 7:10 am PST, June 09, 2004  NASDAQ 2012.42 -11.11 For info, visit access.smallcapnetwork.com S & P 500 1137.72 -4.46 To be removed, please click here Russell 2000 577.90 -0.01 VOLUME 04: ISSUE 45  Feature: BioCurex - For better or worse... Of all the stocks we follow, none has been more active than biomedical device concern BioCurex (BOCX.PK). The action in its shares can be viewed as representative of both the best and worst of trading in the SmallCap market. Although it has had its challenges--as has the overall market--we believe that the shares of BioCurex, at these levels, remains an extremely compelling long-term play for risk-oriented investors. For those others who can't stand the action I would strongly suggest less volatile alternatives. When we brought BioCurex to the attention of the readership last October, the shares were 17 cents. On April 5th, the shares crossed $1.50 a share, and we suggested that investors take some profits. A scant couple of days later, the shares powered up to a high of $3.90. What amazes me is how many people seemed to have ignored our standing rule of selling a portion of a position after a good run to lower the cost base and actually bought shares at what were obviously unsustainable levels. We also have to note that since we Alerted the readership in October, investors had almost six months to pick up ultra-cheap shares at or below 25 cents. Even if one had been on for the whole ride and not sold any, it is very likely the return on those shares is still around 300-400 percent. Rebuilding the faithful While we still like BioCurex, the company remains at a formative stage. Several things have to happen to get it back on investors radar screens, not the least of which is bringing its filings up to date, particularly its audited financials (10k) and restoring its OTC Bulletin Board listing. The sheer pain of trying to trade the shares on the pink sheets has obviously frustrated or even caused potential investors to eschew the stock. Hopefully, both of these issues will be resolved soon. Through all the challenges, BioCurex continues to refine and expose its technologies to potential licensees and interested others. The company will present on its Serum-Recaf? cancer detection blood test at the 3rd Annual Early Detection Research Network (EDRN) Scientific Workshop to be held June 14-16 in Bethesda Maryland. (release below) As we mentioned on May 18th: "Although BioCurex's blood test for cancer, Serum Recaf? has not yet received any regulatory approvals or acceptances, the formative evidence of its efficacy seems to be mounting. The ERDN conference is yet another plank in that endeavor. As you'll note in the release, the attendees read like a who's who of the research and pharmaceutical communities. The more exposure BioCurex musters, the more likely that it will be able to attract the licensees and research partners to carry its business and products forward. If not now, when? Will it be tomorrow? No. Next month? Likely not. But for those risk oriented investors who have followed the progress and travails of this interesting and unique company, we believe that patience will be rewarded in the relatively near future. BioCurex should be a lesson in the vagaries of the SmallCap market. The most strident caveat is that bad things happen to good companies and, while the reverse is also true, we believe that a series of extraneous events has caused the volatility experienced by BioCurex over the past two months. We believe that BioCurex's technologies and future prospects are compelling. We also believe that the company would be further along with its business plan if it hadn't been diverted from its path to deal with inquiries and being banished to the 'pinks'. With any SmallCap, the risk is always the greatest at the formative stage. BioCurex is no different. That said, we've reported the facts--warts and all--over the last eight months. Should the company continue to move forward toward eventual commercialization, all of this noise will quiet. Not to mention the specter of other products that could stem from its initial research and development. Risky? Sure. More than a bit interesting for those risk oriented investors who can see the potential? No doubt.   PRESS RELEASE BioCurex Presents RECAF Blood Test Results at National Cancer Institute Workshop Wednesday June 9, 9:00 am ET RICHMOND, British Columbia--(BUSINESS WIRE)--June 9, 2004--BioCurex Inc. (Pink Sheets:BOCX - News) is pleased to announce that it will be presenting four communications on its blood test for cancer detection at the 3rd Annual Early Detection Research Network (EDRN) Scientific Workshop to be held June 14-16 in Bethesda, Maryland. The EDRN is an initiative of National Cancer Institute's Division of Cancer Prevention. Its objectives are: * Development and testing of promising biomarkers or technologies * Evaluation of promising, analytically proven biomarkers or technologies * Collaboration among academic and industrial leaders in molecular biology, molecular genetics, clinical oncology, computer science, public health and clinical application for early cancer detection * Expand public-private partnership for validation studies by providing access to EDRN resources  BioCurex will be presenting results obtained with its Serum-RECAF(TM) tests on Breast, Stomach, Ovarian and Lung cancers. The detection sensitivity in these cancers is approximately 90% with 95% specificity. Dr. Moro commented: "Presenting our results at this meeting is important for BioCurex because of the resulting exposure to a large number of possible collaborations in the USA. The main purpose of the EDRN - a network of scientists, institutes and companies - is to generate such collaborations, which in turn result in access to samples, validation by American institutions and contacts with major companies in cancer diagnosis. A large variety of cancer samples is critical to the determination of how early we can detect cancer. This presentation will move us towards additional validation by institutions associated with the US National Cancer Institute. We anticipate that our results, which demonstrate that we can use a drop of blood to detect cancer in 90% of cancer patients, will attract the attention of the participants." The EDRN Biomarkers Development Labs include: Johns Hopkins University University of Texas MD Anderson University Maryland University of Colorado Yale University Northwestern University Medical Center Moffitt Cancer Center, University of South Florida University of Michigan University of Texas Southwestern Genetica, Inc. Duke University Thomas Jefferson University University of Pittsburgh Eastern Virginia Medical School University of Washington, Seattle About BioCurex: BioCurex, Inc. is a biotechnology company that is developing products based on patented/proprietary technologies in the area of cancer diagnosis. The technology identifies a cancer marker known as RECAF(TM), which is found on malignant cells from a variety of cancer types but is absent in most normal or benign cells. Our blood test for cancer known as Serum-RECAF(TM) has not yet been approved by the FDA and it is to be used for research purposes only. To find out more about BioCurex (BOCX), visit our website at www.biocurex.com. Note: The Company has not authorized the release of this information in any form that contravenes the Communication Act and will not be responsible for unsolicited massive distribution of this material by e-mail or facsimile by unauthorized parties. Statements in this press release, which are not historical facts, are "forward-looking statements'' within the meaning given to that term in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby. Since these statements involve risks and uncertainties and are subject to change at any time, the Company's actual results could differ materially from expected results. Contact: BioCurex, Inc. Dr. Ricardo Moro, 604-207-9150 Source: BioCurex, Inc.   We Value Your Feedback Got comments, questions or suggestions? Send 'em on over: Editor@smallcapnetwork.com If you wish to send a written request or inquiry, please send it to our physical address: TGR Group, LLC 3525 Del Mar Heights Rd #334 San Diego, CA 92130 Unsubscribe Here D I S C L A I M E R : The SmallCap Digest is an independent electronic publication committed to providing our readers with factual information on selected  publicly traded companies. SmallCap Digest is not a registered investment advisor or broker-dealer. All companies are chosen on the basis of certain financial analysis and other pertinent criteria with a view toward  maximizing the upside potential for investors while minimizing the downside risk, whenever possible.  Moreover, as detailed below, this publication accepts compensation from third party consultants and/or companies which it features for the publication and circulation of the SmallCap Digest or representation on SmallCapNetwork.net.  Likewise, this newsletter is owned by TGR, LLC.  To the degrees enumerated herein,  this newsletter should not be regarded as an independent publication. Click Here to view our compensation on every company we have ever covered, or visit the following web address:  http://access.smallcapnetwork.com/compensation_disclosure.html for our full compensation disclosure and http://access.smallcapnetwork.com/short_term_alerts.html for Trading Alerts compensation and disclosure. TGR Group LLC has been paid a fee of $25,000 and one million newly issued restricted shares by Biocurex for coverage of the company. Additionally, Some of the companies featured in the SmallCap Digest Newsletter pay an ESP (Electronic Service Provider) fee to an affiliated Technology Company for electronic delivery of this newsletter and other web related technology services. Fees range from $3,000 to $5,000 per month. All statements and expressions are the sole  opinions of the editors and are subject to change without notice. A profile, description, or other mention of a company in the newsletter is neither an offer nor solicitation to buy or sell any securities  mentioned. While we believe all sources of information to be factual and reliable, in no way do we represent or guarantee the accuracy thereof, nor the statements made herein. The editor, members of the editor's family, and/or entities with  which the editor is affiliated, are forbidden by company policy to own, buy, sell or otherwise trade stock for their own benefit in the companies who appear in the publication unless specifically disclosed in the newsletter. The profiles, critiques, and other editorial content of the SmallCap Digest and SmallCapNetwork.net may contain forward-looking statements relating to the expected capabilities of the companies mentioned herein. THE READER SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN  SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK. THE INFORMATION FOUND IN THIS PROFILE IS PROTECTED BY THE COPYRIGHT LAWS OF THE UNITED STATES AND MAY NOT BE COPIED, OR REPRODUCED IN ANY WAY WITHOUT THE EXPRESSED, WRITTEN  CONSENT OF THE EDITORS OF SMALLCAPNETWORK.NET. We encourage our readers to invest carefully and read the investor information available at the web sites of  the Securities and Exchange Commission ("SEC") at http://www.sec.gov and/or the National Association of Securities Dealers ("NASD") at http://www.nasd.com. We also strongly recommend that you read the SEC advisory to investors concerning Internet Stock Fraud, which can be found at  http://www.sec.gov/consumer/cyberfr.htm . Readers can review all public filings by companies at the SEC's EDGAR page. The NASD has published information on how to invest carefully at its web site.